BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Borgia G, Maraolo AE, Nappa S, Gentile I, Buonomo AR. NS5B polymerase inhibitors in phase II clinical trials for HCV infection. Expert Opin Investig Drugs 2018;27:243-50. [PMID: 29271672 DOI: 10.1080/13543784.2018.1420780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Denel-bobrowska M, Olejniczak AB. Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020). European Journal of Medicinal Chemistry 2022;231:114136. [DOI: 10.1016/j.ejmech.2022.114136] [Reference Citation Analysis]
2 Luna JM, Saeed M, Rice CM. Taming a beast: lessons from the domestication of hepatitis C virus. Curr Opin Virol 2019;35:27-34. [PMID: 30875640 DOI: 10.1016/j.coviro.2019.02.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
3 Randolph JT, Li T, Chris Krueger A, Heyman HR, Chen HJ, Bow DAJ, Van Handel C, Peterkin V, Carr RA, Stolarik D, Dekhtyar T, Irvin M, Krishnan P, Wagner R, DeGoey DA. Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors. Bioorg Med Chem Lett 2020;30:126986. [PMID: 32046903 DOI: 10.1016/j.bmcl.2020.126986] [Reference Citation Analysis]
4 Shahnazarian V, Ramai D, Reddy M, Mohanty S. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. Ann Gastroenterol 2018;31:541-51. [PMID: 30174390 DOI: 10.20524/aog.2018.0281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Masalova OV, Lesnova EI, Klimova RR, Momotyuk ED, Kozlov VV, Ivanova AM, Payushina OV, Butorina NN, Zakirova NF, Narovlyansky AN, Pronin AV, Ivanov AV, Kushch AA. Genetically Modified Mouse Mesenchymal Stem Cells Expressing Non-Structural Proteins of Hepatitis C Virus Induce Effective Immune Response. Vaccines (Basel). 2020;8. [PMID: 32024236 DOI: 10.3390/vaccines8010062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]